Kidney Transplant Improves Erectile Function, But Recovery Hinges on Baseline Severity

Erectile dysfunction is one of the most common and most quietly endured complications of advanced kidney disease, and a new observational study from a tertiary care centre in South Asia suggests that kidney transplantation can meaningfully reverse it — but only up to a point, and unevenly so depending on how much vascular and metabolic damage a patient carries into the operating room. In a cohort of 41 male renal transplant recipients, mean scores on the validated IIEF-5 questionnaire rose significantly from 14.6 ± 5.7 before transplantation to 19.1 ± 5.6 at six months after surgery, a difference the authors report as statistically significant with a p-value below 0.001. Yet the recovery was far from uniform, and the pattern of who improved — and who did not — offers a technically instructive window into the biology of post-transplant sexual health.

The study, published in the African Journal of Urology, enrolled consecutive male recipients transplanted between January 2021 and December 2024, combining a retrospective arm of 16 patients with a prospective arm of 25. All participants were married, cohabiting men aged 18 to 65 who reported sexual activity before transplantation, a deliberate design choice meant to ensure the IIEF-5 instrument — which is clinically interpretable only in men who engage in or attempt sexual activity — could be applied consistently. Patients with graft dysfunction, graft loss, major psychiatric illness, or erectile dysfunction attributable to a non-renal cause predating their kidney disease were excluded, and none of the included men received phosphodiesterase type 5 inhibitors or any other pharmacological ED treatment before transplantation or during the six-month assessment window.

The baseline picture was sobering. Before transplantation, only 3 of the 41 patients — 7.3 percent — fell into the no-ED category of the IIEF-5 scale, which ranges from 5 to 25 and stratifies severity as severe (5–7), moderate (8–11), mild-to-moderate (12–16), mild (17–21), and normal (22–25). Seventeen men (41.5 percent) had mild ED, 13 (31.7 percent) had mild-to-moderate ED, and 8 (19.5 percent) had moderate or severe disease. The cohort’s mean age was 43.1 ± 9.5 years, hypertension was present in 41.5 percent, diabetes mellitus in 26.8 percent, and 29.2 percent reported smoking. The median duration of pre-transplant dialysis was one year.

Six months after receiving a live-related donor kidney — all procedures performed with a standardized extraperitoneal approach in the iliac fossa and uniform immunosuppression with tacrolimus, mycophenolate mofetil, and corticosteroids — the distribution of severity shifted markedly. The proportion of patients without ED climbed from 7.3 percent to 36.6 percent, while moderate-to-severe ED fell from 19.5 percent to 9.8 percent. Patients with mild-to-moderate dysfunction at baseline showed the greatest improvement, whereas those who began with severe ED showed limited recovery, a gradient the authors interpret as consistent with earlier-stage dysfunction reflecting reversible metabolic and vascular abnormalities while advanced disease may involve irreversible corporal fibrosis, endothelial injury, and neuropathic damage.

The subgroup analyses, though the authors repeatedly caution that the small sample size limits their precision, paint a coherent vascular story. Patients with diabetes mellitus improved by a mean of 3.21 ± 3.0 IIEF-5 points, compared with 5.8 ± 3.5 points among non-diabetic patients (p = 0.04). Hypertensive patients gained 3.4 ± 3.2 points versus 5.6 ± 3.6 for non-hypertensive patients (p = 0.03). Smokers improved by 2.8 ± 2.9 points against 5.3 ± 3.3 for non-smokers (p = 0.05), and men dialyzed for two years or longer gained 3.5 ± 3.1 points compared with 5.7 ± 3.4 for those dialyzed less than two years (p = 0.04). Each of these factors — chronic hyperglycemia, arterial stiffness, smoking-related endothelial injury, and prolonged dialysis exposure with its associated vascular calcification — is a recognized driver of the penile microvascular and neuropathic damage that transplantation alone cannot undo.

The mechanistic rationale for improvement after transplantation is biologically plausible, the authors argue. Restoring renal function reduces uremic toxicity, corrects anemia, normalizes metabolic homeostasis, and improves endocrine balance, addressing several of the reversible contributors to erectile dysfunction in end-stage renal disease, where reported ED prevalence ranges from 60 percent to over 80 percent in dialysis populations. Uremic toxins interfere with the hypothalamic-pituitary-gonadal axis, accelerated atherosclerosis and vascular calcification compromise penile hemodynamics, and autonomic and peripheral neuropathy impair erectile signaling — a cascade that transplantation can partially, but not completely, interrupt.

Notably, the study also documented a phenomenon that pure physiological measures miss: two patients, or 4.8 percent, were classified as sexually inactive at six months despite functioning grafts and, in the authors’ words, objective improvement in erectile scores. The paper suggests that psychological well-being, relationship dynamics, body image concerns, cultural influences, and expectations surrounding sexual performance may all shape post-transplant sexual behavior, underscoring that improvement in questionnaire scores does not automatically translate into restored sexual activity. The authors frame sexual health after transplantation as a multidimensional outcome rather than a purely physiological one.

The study’s limitations are considerable and candidly acknowledged. It was single-center, small, and limited to six months of follow-up, which may not capture longer-term recovery patterns. The mixed retrospective-prospective design introduces potential selection and recall bias, and the requirement for pre-transplant sexual activity may have under-represented patients with the most severe dysfunction, since sexual inactivity itself can be a consequence of advanced kidney disease. Hormonal parameters including serum testosterone and HbA1c were not systematically assessed, penile Doppler ultrasonography and other objective vascular measures were not performed, medication-specific data were not formally analyzed — leaving drugs such as beta-blockers, thiazide diuretics, and SSRIs as potential unmeasured confounders — and psychosocial variables were not evaluated with validated instruments. The subgroup findings, the authors conclude, should be treated as hypothesis-generating rather than definitive evidence of causality.

Even so, the clinical message is pointed. Sexual health, the authors argue, should form part of routine post-transplant follow-up rather than being treated as a secondary concern, particularly in regions like South Asia where late presentation after prolonged dialysis exposure, high rates of diabetes and hypertension, substantial smoking prevalence, and cultural taboos around discussing sexual problems compound the risk of persistent ED after otherwise successful transplantation. Identifying and optimizing modifiable vascular risk factors, they suggest, together with counseling and access to psychological support, may improve long-term sexual outcomes, ideally through a multidisciplinary approach involving urologists, nephrologists, endocrinologists, and mental health professionals.

Larger multicentre studies with longer follow-up, objective vascular and hormonal assessments, and formal evaluation of medication exposure and psychosocial factors are needed to validate these observations and identify which patients are most likely to benefit from targeted interventions. For now, the study adds a South Asian data point to a literature dominated by Western and Middle Eastern cohorts, and it quantifies a trade-off many transplant teams already suspect: transplantation restores a great deal, but the longer the dialysis exposure and the heavier the vascular burden a man carries to surgery, the less of his erectile function comes back.

Subject of Research: Changes in erectile function and associated clinical factors among male renal transplant recipients

Article Title: Erectile Dysfunction in Renal Transplant Recipients: Patterns of Recovery and Determinants of Outcome

Article References: Malik, S. A., Bhat, A. H., Quadir, U., Khawaja, A. R., Para, S. A., Mehdi, S., Raina, A. B., Kannan, G., & Arsalan, S. S. (2026). Erectile Dysfunction in Renal Transplant Recipients: Patterns of Recovery and Determinants of Outcome. African Journal of Urology, 32(1), Article 62. https://doi.org/10.1186/s12301-026-00612-3

Image Credits: AI Generated

DOI: 10.1186/s12301-026-00612-3

Keywords: kidney transplantation, erectile dysfunction, IIEF-5, end-stage renal disease, dialysis duration, diabetes mellitus, hypertension, smoking, sexual health, observational study, transplant outcomes, urology